Quantamental Technologies LLC bought a new position in shares of Chemed Co. (NYSE:CHE) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,800 shares of the company’s stock, valued at approximately $576,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc raised its holdings in shares of Chemed by 2.0% during the third quarter. Vanguard Group Inc now owns 1,861,197 shares of the company’s stock valued at $594,801,000 after purchasing an additional 35,966 shares during the period. Vanguard Group Inc. increased its position in shares of Chemed by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,861,197 shares of the company’s stock worth $594,801,000 after acquiring an additional 35,966 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Chemed by 0.4% during the fourth quarter. Fisher Asset Management LLC now owns 477,261 shares of the company’s stock worth $135,198,000 after acquiring an additional 1,961 shares in the last quarter. Investec Asset Management LTD increased its position in shares of Chemed by 7.7% during the fourth quarter. Investec Asset Management LTD now owns 253,517 shares of the company’s stock worth $71,816,000 after acquiring an additional 18,104 shares in the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd increased its position in shares of Chemed by 7.8% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 194,107 shares of the company’s stock worth $54,986,000 after acquiring an additional 13,963 shares in the last quarter. 86.05% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Chemed stock traded down $2.68 on Wednesday, reaching $337.11. 78,838 shares of the company traded hands, compared to its average volume of 126,087. The company has a market capitalization of $5.29 billion, a P/E ratio of 28.26, a P/E/G ratio of 2.96 and a beta of 1.18. The company has a quick ratio of 0.70, a current ratio of 0.73 and a debt-to-equity ratio of 0.17. Chemed Co. has a 52 week low of $260.03 and a 52 week high of $341.18.
Chemed (NYSE:CHE) last announced its quarterly earnings results on Monday, April 29th. The company reported $2.92 EPS for the quarter, missing the Zacks’ consensus estimate of $2.96 by ($0.04). The business had revenue of $462.03 million for the quarter, compared to analysts’ expectations of $468.28 million. Chemed had a net margin of 11.37% and a return on equity of 35.19%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 earnings per share. Equities analysts expect that Chemed Co. will post 12.65 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 19th. Investors of record on Thursday, May 30th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.36%. The ex-dividend date of this dividend is Wednesday, May 29th. Chemed’s payout ratio is currently 10.06%.
In other news, insider Kevin J. Mcnamara sold 6,000 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $331.67, for a total transaction of $1,990,020.00. Following the sale, the insider now owns 159,334 shares in the company, valued at approximately $52,846,307.78. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George J. Walsh III sold 1,000 shares of the firm’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $328.07, for a total transaction of $328,070.00. Following the sale, the director now owns 7,663 shares in the company, valued at approximately $2,514,000.41. The disclosure for this sale can be found here. Insiders have sold a total of 21,245 shares of company stock worth $6,955,533 over the last 90 days. 3.96% of the stock is currently owned by corporate insiders.
Several research firms have recently commented on CHE. Zacks Investment Research downgraded shares of Chemed from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Oppenheimer upped their price objective on shares of Chemed from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 30th. Royal Bank of Canada upped their price objective on shares of Chemed from $313.00 to $318.00 and gave the stock a “sector perform” rating in a research report on Monday, February 25th. Finally, ValuEngine downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Chemed presently has an average rating of “Hold” and an average target price of $347.00.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://sundanceherald.com/2019/05/22/quantamental-technologies-llc-invests-576000-in-chemed-co-che-stock.html.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Featured Article: How do analysts define an oversold condition?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.